Novodiag® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas
Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.
The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.